MC-38-CEA-1 Cell Line from KERAFAST, INC.

Search, find, compare suppliers for MC-38-CEA-1 Cell Line products.

Edit 
Product NameMC-38-CEA-1 Cell Line
DescriptionSource: Murine C57BL6.
Size1 vial
Concentrationn/a
Applicationsn/a
Other Namesn/a
Gene, Accession, CAS #Accession: CVCL_5I36, CVCL_5I37
Catalog #ENH201-FP
Price$768
Order / More InfoMC-38-CEA-1 Cell Line from KERAFAST, INC.
Product Specific References
  1. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 1991 Jul 15;51(14):3657-62. PubMed PMID: 1712245.
  2. Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother. 1997 Jan;20(1):38-47. PubMed PMID: 9101412.
  3. Zeytin H, Reali E, Zaharoff DA, Rogers CJ, Schlom J, Greiner JW. Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity. J Interferon Cytokine Res. 2008 Feb;28(2):73-87. doi: 10.1089/jir.2007.0063. PubMed PMID: 18279103; PubMed Central PMCID: PMC2532849.
  4. Hand PH, Robbins PF, Salgaller ML, Poole DJ, Schlom J. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol Immunother. 1993;36(2):65-75. PubMed PMID: 8425211.
  5. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 2002 Nov 15;169(10):5780-6. Erratum in: J Immunol. 2003 Mar 15;170(6):3440. PubMed PMID: 12421958.
  6. Liu Y, Wang Y, Xing J, Li Y, Liu J, Wang Z. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities. Drug Des Devel Ther. 2018 Aug 29;12:2645-2654. View Article
  7. Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K. Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. Sci Rep. 2021 Mar 24;11(1):6731.  View Article 
KERAFAST, INC.
KERAFAST, INC.
KERAFAST, INC.
An Absolute Biotech Company
2 Shaker Road, Unit B101
Shirley MA 01464
P: +1-617-336-3228
P: +1-800-546-1760
F: +1-866-727-9826

info@kerafast.com
Tech Support: TechnicalSupport@kerafast.com

https://www.kerafast.com

Profile of KERAFAST, INC.

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.